Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) EBT (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed EBT for 7 consecutive years, with $244.3 million as the latest value for Q4 2025.

  • Quarterly EBT rose 370.38% to $244.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$80.1 million through Dec 2025, up 78.36% year-over-year, with the annual reading at -$80.0 million for FY2025, 78.77% up from the prior year.
  • EBT for Q4 2025 was $244.3 million at Beam Therapeutics, up from -$112.7 million in the prior quarter.
  • The five-year high for EBT was $244.3 million in Q4 2025, with the low at -$200.4 million in Q1 2021.
  • Average EBT over 5 years is -$60.0 million, with a median of -$85.9 million recorded in 2023.
  • The sharpest move saw EBT tumbled 621.93% in 2021, then skyrocketed 485.99% in 2023.
  • Over 5 years, EBT stood at -$64.7 million in 2021, then surged by 42.28% to -$37.3 million in 2022, then surged by 485.99% to $144.2 million in 2023, then tumbled by 162.67% to -$90.4 million in 2024, then skyrocketed by 370.38% to $244.3 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $244.3 million, -$112.7 million, and -$102.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.